Previous Article | Next Article 
Journal of Virology, January 2001, p. 375-383, Vol. 75, No. 1
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.1.375-383.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Characterization of Adenovirus-Induced Inverted
Terminal Repeat-Independent Amplification of Integrated
Adeno-Associated Virus rep-cap Sequences
Jacques
Tessier,1
Gilliane
Chadeuf,1
Pascale
Nony,1
Hervé
Avet-Loiseau,2
Philippe
Moullier,1,* and
Anna
Salvetti1,*
Laboratoire de Thérapie
Génique1 and Laboratoire de
Cytogénétique,2 CHU
Hôtel-Dieu, 44035 Nantes Cedex 01, France
Received 20 July 2000/Accepted 3 October 2000
 |
ABSTRACT |
Stable packaging cell lines expressing the rep and
cap genes for recombinant adeno-associated virus type 2 (rAAV-2) assembly constitute an attractive alternative to transient
transfection protocols. We recently characterized a stable HeLa
rep-cap cell clone (HeRC32) and demonstrated that upon
vector transfection and adenovirus infection, efficient rAAV assembly
correlated with a 100-fold amplification of the integrated
rep-cap sequence with the inverted terminal repeats (ITRs)
deleted. We now report a more detailed analysis of this phenomenon and
highlight the key cellular and viral factors involved. Determination of
the rep-cap copy number of HeRC32 cells indicated that
maximum rep-cap amplification occurred between 24 and
48 h following adenovirus infection. Analysis by pulsed-field gel
electrophoresis of adenovirus-infected HeRC32 cells indicated that
amplified rep-cap sequences were found in an
extrachromosomal form. Amplification of the rep-cap
sequence with the ITRs deleted was not dependent on adenovirus
replication and still occurred when the highly specific adenovirus
polymerase was inactivated. In contrast, amplification was inhibited in
the presence of aphidicolin, indicating that cellular polymerases were
needed. Our study also documented that among the adenovirus gene
products, the DNA-binding protein (DBP) was essential, since rep-cap amplification was severely abrogated when HeRC32
cells were infected at a nonpermissive temperature with an adenovirus mutant encoding a thermosensitive DBP. Furthermore, expression of DBP
alone in HeRC32 cells was sufficient to induce a sustained level of
rep-cap amplification. Finally, immunofluorescence analysis showed that HeRC32 cells expressing the DBP also simultaneously expressed the Rep proteins, suggesting a possible involvement of the
latter in rep-cap amplification. Indeed, the lack of
detectable amplification in an adenovirus-infected stable
rep-cap HeLa cell clone unable to produce Rep proteins
further supported that, among the viral gene products, both the DBP and
Rep proteins are necessary to induce the targeted amplification of the
integrated rep-cap sequences in the absence of the AAV ITRs.
 |
INTRODUCTION |
Adeno-associated virus type 2 (AAV-2) is a human parvovirus that has attracted increasing interest
because of its use as a gene transfer vector (23, 32). The
viral genome consists of a 4.7-kb single-stranded DNA molecule which is
composed of two 145-base inverted terminal repeats (ITRs) flanking two
open reading frames (ORFs), rep and cap. The ITRs
constitute the viral sequences required in cis for DNA
replication and encapsidation. The rep ORF contains two
promoters (p5 and p19) and encodes four regulatory Rep proteins
(1). The two larger Rep proteins, Rep 78 and Rep 68, are
involved in all aspects of the viral life cycle, including regulation
of gene expression and DNA replication. They recognize a specific
binding site present in the ITRs (the Rep binding site), and they can
nick the origin of replication in a strand- and sequence-specific fashion (7, 17, 27, 38). All of the Rep proteins also possess ATPase and helicase activities (31, 40, 41). These activities are essential to the initiation of AAV DNA replication. The
two smaller Rep proteins, Rep 52 and Rep 40, are required for
single-stranded DNA accumulation and encapsidation (6, 11). The cap gene is regulated by the p40 promoter
and encodes three structural proteins, VP1, VP2, and VP3, which
constitute the capsid.
To undergo a productive infection, AAV requires the presence of a
helper virus, adenovirus or herpesvirus. The helper virus, for
instance, adenovirus, plays a role in nearly every step of the AAV life
cycle by promoting AAV gene expression and DNA replication. The
critical adenovirus factors involved in the helper effect are the
products of the E1a, E1b, E4 (orf6), and E2a genes and the
VA1 RNA (2). Among these early adenovirus proteins, the one encoded by the E2a gene, the DNA binding protein (DBP), was shown
to be directly implicated in AAV DNA replication by stimulating the
processivity of DNA polymerization (35), possibly by
stabilizing single-strand templates for replication (36).
Recombinant AAV vectors (rAAV) used for gene therapy are derived from
the wild-type virus by deleting the rep and cap
ORFs and replacing them with the transgene and the transcriptional control elements. The only viral sequences retained in the vector are
the ITRs. To assemble rAAV, the rep and cap genes
are usually provided in trans by transfecting cells with a
plasmid harboring the AAV genome with the ITRs deleted together with
the vector plasmid. Adenovirus helper activities can be provided either
by adenovirus infection or by transfection of a plasmid encoding the
critical adenovirus gene products (15). Several variations of this production scheme have been developed, including the use of
herpesviruses to provide helper functions (10).
Recently, several studies reported the use of packaging cell lines
expressing the rep and cap genes for rAAV
production. The cell lines previously described are all derived from
HeLa cells and harbor one to several copies of the AAV genome with the
ITRs deleted stably integrated in the chromosomes. rAAV is assembled following transfection of the AAV vector plasmid and adenovirus infection (8, 9, 18). Alternatively, the vector can be provided by an adenovirus with E1 deleted, which is then used to infect
the packaging cell line (13, 21).
We previously described a HeLa-derived packaging cell line (HeRC32)
which harbors one copy of an AAV genome with the ITRs deleted (3,
28). Upon vector transfection and wild-type adenovirus infection, we have found that efficient rAAV assembly correlated with a
100-fold amplification of the rep-cap genome
(3). This observation was supported by a similar finding
reported by Liu et al. (21).
The present study was undertaken to further investigate this
phenomenon. Determination of the rep-cap copy number of
HeRC32 cells indicated that maximum rep-cap amplification
occurred between 24 and 48 h following adenovirus infection. A
more detailed analysis by pulsed-field gel electrophoresis indicated
that amplified rep-cap sequences were found in an
extrachromosomal form. Cellular, but not the adenovirus, polymerase
activities were required for amplification to proceed. We also
documented that the DBP is the essential and sufficient adenovirus gene
product, since expression of DBP alone in HeRC32 cells was able to
induce rep-cap amplification. Finally, we also confirmed
that Rep proteins were involved in the establishment of the phenomenon,
since HeRC32 expressing DBP alone also expressed Rep proteins.
Furthermore, rep-cap genome amplification was abrogated in a
stable HeLa clone harboring a deleted rep-cap genome that was unable to produce Rep proteins.
 |
MATERIALS AND METHODS |
Cell lines and viruses.
HeRC32, 293RC21, and TERC21 cell
clones were obtained by cotransfecting plasmid pspRC, which harbors the
rep-cap genome with the ITRs deleted (bp 190 to 4484 of
wild-type AAV), with plasmid PGK-Neo, conferring resistance to G418 on
HeLa, 293, and TE671 (a human medulloblastoma cell line) cells,
respectively. The
Rep-HeLa cell clone was obtained using the
pRCtag/
plasmid, in which 350 bp located at the 5' end of the
rep-cap genome (corresponding to nucleotides [nt] 191 to
540 of the wild-type AAV) was deleted. The isolation and
characterization of HeRC32 and 293RC21 cells have been described
elsewhere (3). TERC21 and
Rep-HeLa cells were similarly
characterized and shown to have one or less than one integrated
rep-cap copy per cell genome. The B50 cell line, kindly
provided by J. Wilson (University of Pennsylvania), is a HeLa-derived
cell clone harboring a stably integrated, rep-cap genome
with the ITRs deleted (13). The adenoviruses used were wild-type adenovirus type 5 (Ad5) (ATCC VR-5) and two thermosensitive strains, one with a mutation in the E2a gene (Ad.ts125) and one with a
mutation in the E2b gene (Ad.ts149) (12). Adenoviruses were produced and titrated on 293 cells using standard procedures (14). The absence of revertants in the purified stock of
Ad.ts125 and Ad.ts149 was tested at a nonpermissive temperature. The
absence of contaminating wild-type AAV in the three parental cell lines (HeLa, 293, and TE671) and the adenovirus stocks was determined by PCR
analysis using rep primers.
Plasmids.
To obtain the CMVDBP construct, plasmid
pMSG-DBP-EN (19) was digested with KpnI, filled
in with T4 polymerase, and subsequently digested with
HindIII. The resulting band containing the E2a gene was
gel purified and inserted into the blunt-ended pRC/CMV plasmid (Promega) which had been digested with HindIII and
XbaI. Plasmid pspRC (3) contained the AAV
genome with the ITRs deleted (nt 190 to 4484 of wild-type AAV) and was
obtained by excising the rep-cap fragment from plasmid
psub201 by XbaI digestion (29) and by inserting
it in the XbaI site of plasmid pSP72 (Promega). The
pRCtag/
plasmid contains a rep-cap sequence with 350 bp
deleted (nt 191 to 540 of the wild-type AAV) followed at the 3' end of the AAV sequences by 404 bp from
X174DNA.
Analysis of total genomic DNA by Southern blotting.
Total
DNA was extracted by lysing the cells in a 10 mM Tris-HCl (pH 7.5)-1
mM EDTA-100 mM NaCl-1% sodium dodecyl sulfate (SDS) solution
containing 500 µg of proteinase K (Boehringer Mannheim)/ml. After
overnight digestion at 50°C, the DNA was extracted twice with
phenol-chloroform and precipitated.
For analysis, DNA was digested with the enzyme indicated, run on a 1%
agarose gel, and transferred under alkaline conditions (NaOH at 0.4 N)
to a Hybond N+ membrane (Amersham). The membrane was
hybridized to a fluorescein-labeled probe (Gene Images random prime
labeling module; Amersham) and incubated overnight at 65°C. The
following day, the membrane was washed in 1× SSC (0.15 M NaCl plus
0.015 M sodium citrate) (Research Organics)-0.1% SDS, and then in
0.1× SSC-0.1% SDS, for 15 min at 65°C each time. The membrane was
then processed according to the manufacturer's protocol (Gene Images
CDP-star detection module; Amersham) and exposed to autoradiography film.
Analysis of total genomic DNA by pulsed-field gel
electrophoresis.
Cells were harvested by trypsinization, washed
with phosphate-buffered saline (PBS) (KCl at 2.5 mM,
KH2PO4 at 1.5 mM, NaCl at 137 mM,
Na2HPO4 at 8 mM [pH 7.4]) at 37°C,
resuspended at 4 × 107 cells/ml, and gently mixed
with an equal volume of a 1% solution of low-melting-point agarose
(SeaPlaque; FMC Bioproducts) in Mg2+-Ca2+-free
PBS precooled at 50°C. The mixture was allowed to solidify in the
cold, and agarose-cell plugs were then treated with proteinase K (2 mg/ml) in the presence of 1% SDS. After washing, the plugs were stored
at 4°C in 20 mM Tris buffer-5 mM EDTA (pH 8.0). For digestion, the
plugs were incubated for 6 h at 37°C with 50 U of enzyme in a
total volume of 300 µl per plug. Electrophoresis was carried out
using 1% agarose gels (SeaKem ME agarose [FMC Bioproducts] in 0.5×
TBE buffer [90 mM Tris, 90 mM borate, 2 mM EDTA [pH 8.0]) at 6 V/cm
for 14 to 20 h with a switching time of 50 to 90 s, using
recirculating 0.5× TBE. After ethidium bromide (EtBr) staining and UV
visualization, the DNA was transferred to a Hybond N+
membrane under alkaline conditions (NaOH at 0.4 N). The membrane was
treated and hybridized as described above.
Immunofluorescence analysis.
Immunofluorescence analysis was
performed on 5 × 104 cells seeded on glass slides.
After being washed for 5 min in PBS, the cells were fixed in 4%
paraformaldehyde in PBS for 20 min at room temperature and then
permeabilized with 2% Triton X-100 in PBS for 20 min at room
temperature (RT). After a wash in PBS, the cells were incubated with
2% bovine serum albumin (BSA) in PBS for 20 min at RT and then
incubated with the appropriate antibody. The primary antibody was
diluted in PBS-0.1% Tween and incubated for 1 h with the fixed
cells at RT. The monoclonal anti-DBP mouse antibody (kindly provided by
A. Levine [26]) was diluted 1/10, and the polyclonal
anti-Rep guinea pig antibodies (kindly provided by J. Kleinschmidt
[39]) were diluted 1/100. Next, the slides were washed
in PBS and then incubated with a fluoresceinated anti-mouse antibody
(Amersham) and a rhodamine-conjugated anti-guinea-pig antibody diluted
1/200 and 1/50, respectively, in PBS-0.1% Tween for 1 h at RT in
the dark. After a wash in PBS, the cells were embedded in Vectashield
mounting medium (Vector Laboratories, Inc.) and analyzed using a
confocal Leica DMiRBE microscope.
Fluorescent in situ hybridization (FISH) analysis.
To obtain
metaphase spread, exponentially growing cells were treated with
colcemid (40 ng/ml) for 1 h at 37°C. After trypsinization and
centrifugation, the cell pellets were resuspended in 75 mM KCl for 35 min at 37°C. After addition of a cold methanol-acetic acid (3:1)
solution, cells were pelleted, then resuspended in the same fixative
solution for 10 min at 4°C, and finally dropped onto slides. Slides
were air dried, and the DNA was denatured in 70% formamide-2× SSC
(pH 7.0) for 1 min at 75°C. Slides were then dehydrated in an
ice-cold ethanol series (70, 85, and 100% for 1 min each) and air
dried. Hybridization was performed overnight at 37°C using a
fluorescein-labeled probe according to the manufacturer's protocol
(Nick Translation Reagent Kit; Vysis Inc.). Slides were then washed
sequentially in 2× SSC for 2 min at 75°C and in 2× SSC-0.1%
Triton for 2 min at RT. After being air dried in the dark, slides were
dehydrated and mounted with an antifade 4',6'-diamidino-2-phenylindole (DAPI) solution. Hybridization signals were visualized by using a Zeiss
Axioplan 2 fluorescence microscope with a oil immersion objective.
 |
RESULTS |
AAV rep-cap gene amplification is induced
preferentially in adenovirus-infected HeLa-derived cell clones.
The initial observation underlying this study was made using a
HeLa-derived cell clone harboring one integrated copy of
rep-cap genome with an ITR deletion (HeRC32 cells)
(3). When HeRC32 cells were infected with wild-type
adenovirus, the integrated rep-cap copies underwent a
dramatic amplification, leading to a 100-fold increase in the
rep-cap copy number, as evidenced by Southern blot analysis
of total DNA and hybridization with a rep probe (Fig.
1). The determination of the
rep-cap copy number at different time points indicated that
amplification occurred mainly between 24 and 48 h following
adenovirus infection. After the 48-h time point, no significant
increase was detected. To exclude the possibility that this phenomenon
was due to an intrinsic property of the HeRC32 cell clone, the same
analysis was performed with another HeLa-derived rep-cap
cell clone (B50), which harbors five integrated rep-cap
copies (13). Despite the different origin of the B50
cells, rep-cap sequences were similarly amplified following adenovirus infection (Fig. 2, lanes 6 and
7). Interestingly, the number of rep-cap copies found in the
B50 cells after adenovirus infection was similar to that measured in
HeRC32 cells, suggesting that the level of amplification was not
dependent upon the initial rep-cap copy number (Fig. 2;
compare lanes 5 and 7). The same results were obtained using a
cap probe (data not shown), indicating that the entire
rep-cap genome had undergone amplification. In addition,
other cellular or viral endogenous sequences such as those
corresponding to the elongation factor 1-
(EF1-
), bilirubin glycuronyl transferase 1 (BGT1), and human papillomavirus (HPV) genes
were not found to be amplified upon adenovirus infection (data not
shown), suggesting that the amplification phenomenon was restricted to
rep-cap-containing sequences.

View larger version (89K):
[in this window]
[in a new window]
|
FIG. 1.
Kinetics of rep-cap amplification upon
adenovirus infection. HeRC32 cells were infected with Ad5 at an MOI of
50. Total genomic DNA extracted at 24, 48, and 72 h postinfection
was digested with PstI and analyzed on a Southern blot using
a rep probe (1.4 kb) obtained by digesting plasmid pspRC
with PstI. The position of the expected 1.4-kb
rep band is indicated. The standard samples with 1, 10, and
100 rep-cap copies per cell were obtained by adding 36, 360, and 3,600 pg, respectively, of plasmid pspRC to 10 µg of total
genomic DNA from noninfected HeLa cells. Lane 1, DNA from
adenovirus-infected HeLa cells; lanes 2, 3, and 4, standard
rep-cap genome copies; lane 5, DNA from noninfected HeRC32
cells; lanes 6, 7, and 8, DNA extracted from HeRC32 cells 24, 48, and
72 h post-adenovirus infection, respectively.
|
|

View larger version (68K):
[in this window]
[in a new window]
|
FIG. 2.
Analysis of rep-cap amplification in
different stable rep-cap cell clones. The stable
rep-cap cell clones analyzed are HeRC32, B50 (derived from
HeLa cells [13]), 293RC21 (derived from 293 cells), and
TERC21 (derived from TE671 cells). rep-cap amplification was
analyzed as described in the legend to Fig. 1 following adenovirus
infection of the cells at an MOI of 50 (for HeLa-derived cells), 10 (for 293-derived cells), or 25 (for TE671-derived cells). Lanes 1 and
2, standard rep-cap genome copies; lane 3, DNA from
adenovirus-infected HeLa cells; lanes 4, 6, 8, and 10, DNA from
noninfected HeRC32, B50, 293RC21, and TERC21 cells, respectively; lanes
5, 7, 9, and 11, DNA from adenovirus-infected HeRC32, B50, 293RC21, and
TERC21 cells, respectively.
|
|
Further analyses were conducted to determine if rep-cap
amplification could also take place in other rep-cap stable
cell clones derived from other cell backgrounds. For this purpose, two
stable cell clones derived from low-passage-number 293 (293RC21) and TE671 cells (TERC21) and harboring integrated rep-cap
genomes were similarly analyzed by Southern blotting. Following
adenovirus infection, the endogenous rep-cap sequences were
amplified only two- to threefold in the 293RC21 cells, a level much
lower than that observed in HeRC32 and B50 cells (Fig. 2, lanes 8 and
9). In TERC21 cells, no rep-cap amplification was detected
(Fig. 2, lanes 10 and 11). Overall, these analyses suggested that
adenovirus-induced rep-cap amplification occurred
preferentially in the HeLa-derived cell clones analyzed.
Amplified rep-cap sequences are extrachromosomal.
The next question concerned the status of the amplified
rep-cap sequences. We wished to determine if the amplified
rep-cap sequences are found in an integrated or in an
extrachromosomal form. For this, rep-cap sequences present
in control and adenovirus-infected HeRC32 and B50 cells were analyzed
by FISH. Metaphase spreads of uninfected cells confirmed the presence
of rep-cap sequences in an integrated state in both cell
clones (Fig. 3A and D). The analysis
performed 48 h following adenovirus infection showed an increase
in the rep-cap signal, which appeared as a large dot (Fig.
3B and E). This result illustrated the amplification phenomenon previously detected by Southern blotting. However, because of the
growth arrest induced by the adenovirus infection, it was not possible
to visualize metaphases in these cells and thus to distinguish if the
rep-cap signal following amplification colocalized with a
chromosomal structure. To try to visualize intermediate forms of
amplification, HeRC32 cells were infected with wild-type adenovirus at
a suboptimal multiplicity of infection (MOI) of 1. In this case,
different patterns could be observed. Particularly, some nuclei
displayed a strong rep-cap signal, which was not
concentrated in a single spot but was rather diffuse (Fig. 3C). This
result suggested that amplified rep-cap sequences were
present in an extrachromosomal form.

View larger version (59K):
[in this window]
[in a new window]
|
FIG. 3.
FISH analysis of noninfected and adenovirus-infected
HeRC32 and B50 cells. Cells were prepared for FISH analysis as
described in Materials and Methods, and were analyzed using a
fluorescein-labeled rep-cap probe (4.5 kb) obtained by
digesting pspRC with XbaI. (A) noninfected HeRC32 cells; (B)
adenovirus-infected HeRC32 cells (MOI, 50); (C) adenovirus-infected
HeRC32 cells (MOI, 1); (D) noninfected B50 cells; (E)
adenovirus-infected B50 cells (MOI, 50); (F) noninfected control HeLa
cells. Magnification, ×1,000.
|
|
To confirm this observation, total genomic DNA extracted from infected
and uninfected HeRC32 cells, was analyzed by pulsed-field gel
electrophoresis followed by Southern blot analysis using a rep probe. Digestion of total DNA extracted from uninfected
HeRC32 cells with NotI, which does not cut the
rep-cap DNA, released a unique high-molecular-weight band
presumably containing the integrated rep-cap copies (Fig.
4A, lane 2). Following adenovirus infection of HeRC32 cells, an additional, faster-migrating form was
detected (Fig. 4A, lane 4). Neither of these signals was detected by
using DNA from control or adenovirus-infected HeLa cells (Fig. 4A,
lanes 1 and 3). The highest-molecular-weight band seen with DNA from
adenovirus-infected HeRC32 cells was not detected by using undigested
DNA (Fig. 4B, lane 3), highlighting the specificity of the probe.
Conversely, the faster-migrating band was still detected using by
undigested DNA (Fig. 4B, lane 3), suggesting that this form
corresponded to an extrachromosomal molecule containing rep-cap sequences.

View larger version (76K):
[in this window]
[in a new window]
|
FIG. 4.
Analysis of rep-cap amplified DNA molecules
by pulsed-field gel electrophoresis. Samples for pulsed-field gel
electrophoresis were prepared from noninfected or adenovirus-infected
HeRC32 cells (MOI, 50) as described in Materials and Methods and were
analyzed using a rep probe (1.4 kb). Where indicated, DNA
was digested with NotI, which does not cut in the
rep-cap genome. (A) Lanes 1 and 2, noninfected HeLa and
HeRC32 cells, respectively; lanes 3 and 4, adenovirus-infected (48 h)
HeLa and HeRC32 cells, respectively. (B) Lanes 1 and 2, noninfected
HeRC32 cells; lanes 3 and 4, adenovirus-infected (48 h) HeRC32 cells.
The two arrows indicate the positions of the integrated (a) and
extrachromosomal (b) rep-cap fragments.
|
|
Cellular but not adenovirus polymerases are involved in the
amplification process.
The above results indicated that upon
adenovirus infection, integrated rep-cap sequences were
amplified and extruded from the chromosomal structure. To further
elucidate this phenomenon, it was important to determine if the
amplification of rep-cap sequences resulted from the
activity of cellular or adenovirus polymerases. To answer this
question, rep-cap amplification was analyzed after infection
of HeRC32 cells with an adenovirus mutant harboring a thermosensitive
mutation in the E2b gene encoding the viral polymerase (Ad.ts149).
HeRC32 cells were infected with Ad.ts149 and maintained for 48 h
at either 32°C (the permissive temperature) or 39°C (the
nonpermissive temperature). Analysis of total DNA by Southern blotting
and hybridization with a rep probe indicated that
inactivation of the adenovirus polymerase at 39°C did not inhibit
rep-cap amplification, which reached a level similar to that
observed in cells infected at 32°C (Fig. 5A, lanes 6 and 7). This result indicated
that the adenovirus polymerase was not involved in the
rep-cap amplification and further suggested the involvement
of cellular polymerases in this process.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 5.
(A) Effect of thermosensitive adenovirus mutants on
rep-cap amplification. HeRC32 cells were infected with
Ad.ts125 or Ad.ts149 at an MOI of 50 and incubated at either 32 or
39°C. Forty-eight hours later, total genomic DNA was extracted and
analyzed using a rep probe as indicated in the legend to
Fig. 1. Lanes 1 and 2, standard rep-cap genome copies; lane
3, DNA from noninfected HeRC32 cells; lanes 4 and 5, DNA from HeRC32
cells infected with Ad.ts125 at 32 and 39°C, respectively; lanes 6 and 7, DNA from HeRC32 cells infected with Ad.ts149 at 32 and 39°C,
respectively. The position of the expected 1.4-kb rep band
is indicated. (B) Effect of aphidicolin on adenovirus-induced
rep-cap amplification. HeRC32 cells were infected with Ad5
(MOI, 50) for 2 h at 37°C and then either left untreated or
incubated in the presence of aphidicolin at the final concentrations
indicated. Two micrograms of total DNA extracted 48 h later was
analyzed by dot blot using a rep (1.4-kb) or DBP (1.6-kb)
probe. The DBP probe was obtained by digesting plasmid pMSG-DBP-EN
(19) with HindIII and SfiI. Lane
1, DNA from noninfected HeRC32 cells; lane 2, DNA from
adenovirus-infected HeRC32 cells; lanes 3 to 6, DNA from
adenovirus-infected HeRC32 cells incubated in the presence of
increasing concentrations of aphidicolin.
|
|
To confirm this hypothesis, rep-cap amplification was
analyzed in the presence of an inhibitor of cellular polymerases. For this, HeRC32 cells were infected with wild-type adenovirus for 2 h. After this period, the medium was changed and cells were incubated
with different concentrations of aphidicolin, a drug known to inhibit
the activity of polymerases
,
, and
(16, 20).
Two days later, DNA was analyzed by dot blot and hybridized either to a
rep probe, to monitor rep-cap amplification, or
to an E2a probe, to monitor the effect of the drug on adenovirus replication. As shown in Fig. 5B, the addition of aphidicolin strongly
inhibited rep-cap amplification, with a maximum effect reached at a concentration of 2.5 µg/ml. In contrast, aphidicolin did
not inhibit adenovirus replication. Overall, these results indicated
that a cellular polymerase(s) was involved in the amplification process.
rep-cap amplification can be induced in the presence of
DBP and Rep proteins.
Previous results indicated that the
adenovirus E2b gene was not necessary for rep-cap
amplification. To further investigate the role of adenovirus, the same
analysis was performed using another adenovirus mutant harboring a
thermosensitive mutation in the E2a gene encoding the DBP (Ad.ts125).
As previously described, HeRC32 cells were infected with Ad.ts125 and
maintained for 48 h at either 32°C (the permissive temperature)
or 39°C (the nonpermissive temperature). Analysis of the
rep-cap copy number by Southern blotting indicated that
amplification was severely reduced upon inactivation of the DBP (Fig.
5, lanes 4 and 5). This result suggested that this adenovirus factor
might play a key role in the observed phenomenon. To confirm this
hypothesis, a plasmid harboring the E2a gene under the control of the
cytomegalovirus (CMV) promoter (CMVDBP) was transfected into HeRC32
cells 6 h prior to infection with Ad.ts125 at both the permissive
and nonpermissive temperatures. Analysis of rep-cap DNA
48 h after infection revealed that rep-cap amplification could be restored to normal levels when cells were infected with Ad.ts125 at 39°C and transfected with CMVDBP (Fig. 6, lanes 7 and 8).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 6.
(A) Effect of the adenovirus DBP on rep-cap
amplification. HeRC32 cells were infected with Ad.ts125 (MOI, 50) at
the indicated temperature, and total DNA was analyzed by Southern
blotting using a rep probe (1.4 kb) as described in the
legend to Fig. 1. Where indicated, the CMVDBP plasmid (10 µg) was
transfected into 4 × 106 HeRC32 cells using Exgen
(EuroMedex), either alone or 6 h prior to adenovirus infection. In
this case, the transfection was done at 37°C and the cells were
switched to the indicated temperature immediately after adenovirus
infection. Lane 1, DNA from noninfected HeLa cells; lanes 2, 3, and 4, standard rep-cap genome copies; lane 5, DNA from HeRC32
cells infected with Ad.ts125 at 32°C; lane 6, DNA from HeRC32 cells
transfected with CMVDBP and infected with Ad.ts125 at 32°C; lane 7, DNA from HeRC32 cells infected with Ad.ts125 at 39°C; lane 8, DNA
from HeRC32 cells transfected with CMVDBP and infected with Ad.ts125 at
39°C; lane 9, DNA from noninfected HeRC32 cells; lane 10, DNA from
HeRC32 cells transfected with the CMVDBP plasmid. (B) Analysis of
rep-cap amplification in Rep-HeLa cells. Total DNA was
extracted from uninfected (lane 1) and adenovirus-infected (lane 2)
Rep-HeLa cells, digested with PstI, and analyzed on a
Southern blot as previously indicated. Since the deletion in the
rep sequence removes one PstI site, the size of
the expected band is 3.8 kb.
|
|
To further validate the role of DBP in the amplification process,
HeRC32 cells were transfected with plasmid CMVDBP alone and
analyzed for rep-cap copy number by Southern blotting. A
detectable level of amplification was seen under this condition (Fig.
6A, lane 10). The relatively low level of amplification seen upon transfection of CMVDBP was likely due to the inefficient transfection of this plasmid in HeRC32 compared to the efficiency of adenovirus infection.
To verify this, HeRC32 cells transfected with the CMVDBP plasmid were
analyzed by FISH to detect rep-cap amplification. As shown
in Fig. 7A and B, an amplified
rep-cap signal was detected in a small proportion of cells,
reflecting the overall transfection efficiency (approximately 5%). As
previously observed in adenovirus-infected HeRC32 cells, it was not
possible to visualize metaphases in cells displaying an amplified
rep-cap signal. No amplification was observed using a
control plasmid (data not shown). These results indicated that among
the adenovirus genes, the gene encoding the DBP was sufficient to
support rep-cap amplification.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 7.
FISH analysis of HeRC32 cells transfected with the
CMVDBP plasmid. A total of 4 × 106 HeRC32 cells were
transfected with 10 µg of the CMVDBP plasmid using Exgen (EuroMedex).
Forty-eight hours later, the cells were prepared for FISH analysis as
indicated in Materials and Methods. The samples were analyzed using a
fluorescein-labeled rep-cap probe. Two typical examples of
rep-cap amplification are shown. (A) Untransfected HeRC32
cells; (B and C) transfected HeRC32 cells. Magnification, ×1,000.
|
|
If these results clearly identified the DBP as the adenovirus factor
able to induce the amplification process, they did not exclude the
possibility that other proteins, and particularly the Rep proteins,
participated in this phenomenon. To elucidate this point, HeRC32 cells
transfected with the CMVDBP plasmid were first analyzed by
immunofluorescence to detect Rep protein synthesis. As shown in Fig.
8, both spliced and unspliced Rep
proteins were detected in cells transfected with the CMVDBP plasmid
alone. This result indicated that Rep proteins were expressed in cells
transfected with the CMVDBP plasmid and further suggested their
involvement in the amplification process. To confirm this hypothesis, a
stable cell clone harboring a mutated rep-cap genome
(
Rep-HeLa), unable to produce Rep proteins, was isolated. As
expected, no amplification of integrated rep-cap sequences
was detected following wild-type adenovirus infection (Fig. 6B).
Overall, these results strongly suggested that the Rep proteins were
implicated in the amplification process.

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 8.
Detection of Rep and DBP proteins following transfection
of the CMVDBP plasmid into HeRC32 cells. A total of 6 × 104 HeRC32 cells grown on glass slides were transfected
with 0.4 µg of the CMVDBP plasmid. Forty-eight hours later, the cells
were fixed and analyzed by immunofluorescence using an anti-DBP
(26) and an anti-Rep 68/40 (A, B, and C) or anti-Rep 78/52
(D, E, and F) antibody (39). Cells were photographed with
either a fluorescein (A and D) or a rhodamine (B and E) filter. In
panels C and F, the two images are superimposed. Magnification,
×1,000.
|
|
 |
DISCUSSION |
rep-cap amplification, first mentioned by Liu et al.
(21), was described using the HeRC32 cell line
(3). Using Southern blot analysis we showed that 48 h
after adenovirus infection, the rep-cap copy number was
increased at least 100-fold. This increase in the number of
rep-cap genome copies correlated with both a high level of
Rep and Cap protein synthesis and rAAV assembly, thus supporting the
idea that the newly amplified rep-cap copies were used as
templates for rep and cap gene expression.
In this study, we further investigated the mechanisms underlying
rep-cap amplification. First, by comparing different stable rep-cap cell lines, we found that among the various cell
backgrounds examined, rep-cap amplification occurred
preferentially in the HeLa-derived cell clones. rep-cap
sequences integrated in the genome of 293 and TE671 cells were barely
amplified (Fig. 2). This observation suggests that the HeLa cell
background is critical for this phenomenon, and it can be related to
the fact that, at least in our hands, this cell type is also optimal
for rAAV production (3). Interestingly, cellular extracts
from uninfected HeLa cells have been reported to be able to support in
vitro AAV replication in the presence of Rep proteins (24,
37). These characteristics might be related to the presence in
these cells of several copies of an HPV18 genome in which E2 is deleted
(22). Indeed, HPV has also been reported to exert a helper
activity for AAV replication (25, 34). Alternatively,
these properties might be related to the presence of a cell
type-specific factor. We are currently testing these hypotheses by
examining if rep-cap amplification can also occur in stable
rep-cap cell clones derived from SiHa cells which, like the
HeLa cells, harbor the HPV genome (22).
Second, this study examined the status of the amplified
rep-cap sequences. The data obtained by FISH analysis
confirmed the tremendous increase in the rep-cap copy number
detected by Southern blotting (Fig. 3). However, a clear-cut analysis
of the status of these amplified sequences was obtained only after
pulsed-field gel electrophoresis of the DNA. Using this method, it was
found that amplified DNA is present in an extrachromosomal form
48 h after adenovirus infection (Fig. 4).
Amplification of endogenous cellular genes, and particularly oncogenes,
has been extensively described as a common phenomenon occurring during
tumor progression. Furthermore, cellular gene amplification can also
occur as a response to various drugs such as DNA-damaging agents
(30). Amplified sequences are found either integrated,
under the form of homogeneously staining regions (HSR), or
extrachromosomally. In this case, amplified sequences are usually identified as double-minute chromosomes (DMs). These
high-molecular-weight circular DNA molecules autonomously replicate
using a cellular replication origin, but, lacking centromeres, they do
not segregate with chromosomes and as a consequence are usually lost
upon cell division (33). A third class of amplified
structures has also been described as submicroscopic circular DNA
molecules termed "episomes". Although the precise mechanism of gene
amplification is still unclear, it has been proposed that DMs, which
are the predominant cytogenic manifestation of gene amplification, are derived from smaller episomes which progressively enlarge and can lead
to HSR by integrating back in the chromosomal structure (33). The extrachromosomal rep-cap sequences
detected in our model might be defined as episomal structures
resembling those leading to DMs. It should be noted that
rep-cap amplification was not observed following treatment
of the cells with DNA-damaging agents such as hydroxyurea, UV exposure,
and the X-ray irradiation (data not shown). As such, rep-cap
amplification could represent a unique model of gene amplification.
Third, this study aimed at identifying the minimal cellular and viral
factors involved in rep-cap amplification. Using an adenovirus harboring a thermosensitive mutation in the E2b gene, we
found that rep-cap amplification still occurred even in the absence of a functional adenovirus polymerase (Fig. 5A). This result
also indicated that adenovirus replication per se was not required for
rep-cap amplification. As shown in the case of wild-type AAV
DNA replication (24), we further demonstrated that
rep-cap amplification can be completely abolished by
treating the cells with aphidicolin (Fig. 5B), a drug known to inhibit
the activity of the cellular polymerases
,
, and
(16,
20). The similarity to wild-type AAV replication extends further
to the requirement for a functional DBP. Indeed, by using an adenovirus
harboring a thermosensitive mutation in the E2a gene, it was shown that the DBP was essential for rep-cap amplification (Fig. 5A and
6A). This protein is the only adenovirus factor directly implicated in
AAV DNA replication. Ward et al. recently showed that DBP was essential
in vitro, to increase processing of DNA replication, presumably by
stabilizing single-stranded templates (35, 36). The
involvement of DBP in rep-cap amplification was further
demonstrated by transfecting a plasmid encoding this protein into
HeRC32 cells and by showing that amplification events could be detected
by Southern blotting and FISH analysis (Fig. 6A and 7). Although these
results do not exclude the implication of other adenovirus factors in
rep-cap amplification, they clearly demonstrated that the
DBP alone is sufficient.
The last question concerned the role of the AAV gene products and
particularly the Rep proteins. We found that, upon transfection of the
CMVDBP plasmid, both spliced and unspliced Rep proteins were detected
(Fig. 8). This observation, which is in agreement with a previous
report by Chang and Shenk, who demonstrated that DBP was able to
trans-activate the p5 promoter (4), suggested the possible involvement of Rep proteins in the amplification process.
Abolishment of Rep proteins in adenovirus-infected stable HeLa cell
clones (
Rep-HeLa) harboring a rep-cap genome unable to
produce Rep proteins also suggested that they are needed for amplification (Fig. 6B). Importantly, the fact that Rep 78 and Rep 52 were still expressed in Ad.ts125-infected HeRC32 cells at a
nonpermissive temperature (data not shown), i.e., under conditions in
which amplification no longer occurred (Fig. 5A), further confirmed that Rep proteins, and particularly Rep 78 and Rep 52, were not sufficient alone and that a functional DBP was also needed to induce
rep-cap amplification. Finally, although the DBP is able to
stimulate Rep protein synthesis alone (4), it is possible that a maximal level of amplification requires an optimal rate of
rep gene expression that is obtained only in the presence of the E1a gene product (5).
Given these findings, we assume that rep-cap amplification
is the result of the activity of at least three main factors: DBP, cellular polymerases, and Rep proteins. It remains to be seen if
rep-cap amplification results from the presence of a
cellular origin of replication or from one present in the viral genome. Analysis of stable rep-cap cell clones harboring critical
deletions of the AAV rep-cap sequences will help resolve
this issue. It is possible to envision that the combination of these
trans (Rep, DBP, cellular polymerases, and presumably some
unknown factor related to HeLa cells) and cis (a viral or
cellular origin of replication) elements generate unscheduled
overreplication of rep-cap sequences. The fact that the
endogenous integrated rep-cap copies are still detected in
adenovirus-infected HeRC32 cells (Fig. 4B) indicates that the original
rep-cap sequences are not excised from the chromosome during
rep-cap amplification. Further analysis of these
extrachromosomal molecules together with the sequence of the integrated
rep-cap genomes will help define the mechanism of amplification.
In conclusion, our observations constitute a first step toward the
elucidation of the mechanism underlying rep-cap
amplification in HeLa cells. These findings have important implications
for the development of future generations of rep-cap cell
lines able to produce optimal levels of Rep and Cap proteins upon
adenovirus infection.
 |
ACKNOWLEDGMENTS |
We are grateful to Michael Linden and Matthew Weitzman for
critical reading of the manuscript. We thank Marie-Claire Devilder and
Jean-Paul Moisan for technical assistance.
This work was supported by the Association Française contre les
Myopathies (AFM), Vaincre les Maladies Lysosomales (VML), the
Association Nantaise de Thérapie Génique (ANTG), and the Fondation pour la Thérapie Génique en Pays de la Loire.
P.M. was supported by a sponsored research agreement from Genopoietic Inc.
J. Tessier and G. Chadeuf contributed equally to this work.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratoire de
Thérapie Génique, CHU Hôtel-Dieu, Bâtiment Jean
Monnet, 30 Avenue Jean Monnet, 44035 Nantes cedex 01, France. Phone:
33240087490. Fax: 33240087491. E-mail for Philippe Moullier:
moullier{at}sante.univ-nantes.fr. E-mail for Anna Salvetti:
salvetti{at}sante.univ-nantes.fr.
 |
REFERENCES |
| 1.
|
Berns, K. I., and C. Giraud.
1996.
Biology of adeno-associated virus.
Curr. Top. Microbiol. Immunol.
218:1-23[Medline].
|
| 2.
|
Carter, B. J.
1990.
Adeno-associated virus helper functions, p. 255-282.
In
P. Tijssen (ed.), Handbook of parvoviruses. CRC Press, Boca Raton, Fla.
|
| 3.
|
Chadeuf, G.,
D. Favre,
J. Tessier,
N. Provost,
P. Nony,
J. Kleinschmidt,
P. Moullier, and A. Salvetti.
2000.
Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome.
J. Gene Med.
2:260-268[CrossRef][Medline].
|
| 4.
|
Chang, L.-S., and T. Shenk.
1990.
The adenovirus DNA-binding protein stimulates the rate of transcription directed by adenovirus and adeno-associated virus promoters.
J. Virol.
64:2103-2109[Abstract/Free Full Text].
|
| 5.
|
Chang, L.-S.,
Y. Shi, and T. Shenk.
1989.
Adeno-associated virus p5 promoter contains an adenovirus E1A-inducible element and a binding site for the major late transcription factor.
J. Virol.
63:3479-3488[Abstract/Free Full Text].
|
| 6.
|
Chejanovsky, N., and B. J. Carter.
1989.
Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral replication.
Virology
173:120-128[CrossRef][Medline].
|
| 7.
|
Chiorini, J. A.,
M. D. Weitzman,
R. A. Owens,
E. Urcelay,
B. Safer, and R. M. Kotin.
1994.
Biologically active Rep proteins of adeno-associated virus type 2 produced as fusion proteins in Escherichia coli.
J. Virol.
68:797-804[Abstract/Free Full Text].
|
| 8.
|
Clark, K. R.,
X. Liu,
J. P. McGrath, and P. R. Johnson.
1999.
Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses.
Hum. Gene Ther.
10:1031-1039[CrossRef][Medline].
|
| 9.
|
Clark, K. R.,
F. Voulgaropoulou,
D. M. Fraley, and P. R. Johnson.
1995.
Cell lines for the production of recombinant adeno-associated virus.
Hum. Gene Ther.
6:1329-1341[Medline].
|
| 10.
|
Conway, J. E.,
C. M. J. ap Rhys,
I. Zolotukhin,
S. Zolotukhin,
N. Muzyczka,
G. S. Hayward, and B. J. Byrne.
1999.
High-titer recombinant adeno-associated virus production utilizing a recombinant herpes simplex virus type I expressing AAV-2 rep and cap.
Gene Ther.
6:986-993[CrossRef][Medline].
|
| 11.
|
Dubielzig, R.,
J. A. King,
S. Weger,
A. Kern, and J. A. Kleinschmidt.
1999.
Adeno-associated virus type 2 protein interactions: formation of pre-encapsidation complexes.
J. Virol.
73:8989-8998[Abstract/Free Full Text].
|
| 12.
|
Ensinger, M. J., and H. S. Ginsberg.
1972.
Selection and preliminary characterization of temperature-sensitive mutants of type 5 adenovirus.
J. Virol.
10:328-339[Abstract/Free Full Text].
|
| 13.
|
Gao, G.-P.,
G. Qu,
L. Z. Faust,
R. K. Engdahl,
W. Xiao,
J. V. Hughes,
P. W. Zoltick, and J. M. Wilson.
1998.
High-titer adeno-associated viral vectors from a rep/cap cell line and hybrid shuttle virus.
Hum. Gene Ther.
9:2353-2362[Medline].
|
| 14.
|
Graham, F. L., and L. Prevec.
1991.
Manipulation of adenovirus vectors, p. 109-128.
In
E. J. Murray (ed.), Gene transfer and protocol. The Humana Press, Inc., Clifton, N.J.
|
| 15.
|
Grimm, D., and J. A. Kleinschmidt.
1999.
Progress in adeno-associated virus type 2 vector production: promises and prospects for clinical use.
Hum. Gene Ther.
10:2445-2450[CrossRef][Medline].
|
| 16.
|
Ikegami, S.,
T. Taguchi,
M. Ohashi,
M. Oguro,
H. Nagano, and Y. Mano.
1978.
Aphidicolin prevents mitotic cell division by interfering with the activity of DNA polymerase-alpha.
Nature
275:458-460[CrossRef][Medline].
|
| 17.
|
Im, D. S., and N. Muzyczka.
1990.
The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity.
Cell
61:447-457[CrossRef][Medline].
|
| 18.
|
Inoue, N., and D. W. Russel.
1998.
Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors.
J. Virol.
72:7024-7031[Abstract/Free Full Text].
|
| 19.
|
Klessig, D. F.,
D. E. Brough, and V. Cleghon.
1984.
Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell.
Mol. Cell. Biol.
4:1354-1362[Abstract/Free Full Text].
|
| 20.
|
Lee, M. Y. W. T.,
C.-K. Tan,
K. M. Downey, and A. G. So.
1981.
Structural and functional properties of calf thymus DNA polymerase delta.
Prog. Nucleic Acids Res. Mol. Biol.
26:83-96[Medline].
|
| 21.
|
Liu, L.,
K. R. Clark, and P. R. Johnson.
1999.
Production of recombinant adeno-associated virus vectors using a packaging cell line and a hybrid recombinant adenovirus.
Gene Ther.
6:293-299[CrossRef][Medline].
|
| 22.
|
Meissner, J. D.
1999.
Nucleotide sequences and further characterization of human papillomavirus DNA present in the CaSki, SiHa and HeLa cervical carcinoma cell lines.
J. Gen. Virol.
80:1725-1733[Abstract].
|
| 23.
|
Muzyczka, N.
1992.
Use of adeno-associated virus as a general transduction vector for mammalian cells.
Curr. Top. Microbiol. Immunol.
158:97-129[Medline].
|
| 24.
|
Ni, T. H.,
W. F. McDonald,
I. Zolotukhin,
T. Melendy,
S. Waga,
B. Stillman, and N. Muzyczka.
1998.
Cellular proteins required for adeno-associated virus DNA replication in the absence of adenovirus coinfection.
J. Virol.
72:2777-2787[Abstract/Free Full Text].
|
| 25.
|
Ogston, P.,
K. Raj, and P. Beard.
2000.
Productive replication of adeno-associated virus can occur in human papillomavirus type 16 (HPV-16) episome-containing keratinocytes and is augmented by the HPV-16 E2 protein.
J. Virol.
74:3494-3504[Abstract/Free Full Text].
|
| 26.
|
Reich, N. C.,
P. Sarnow,
E. Duprey, and A. J. Levine.
1983.
Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein.
Virology
128:480-484[CrossRef][Medline].
|
| 27.
|
Ryan, J. H.,
S. Zolotukhin, and N. Muzyczka.
1996.
Sequence requirements for binding of Rep68 to the adeno-associated virus terminal repeats.
J. Virol.
70:1542-1553[Abstract].
|
| 28.
|
Salvetti, A.,
G. Chadeuf,
S. Orève,
D. Favre,
Y. Cherel,
P. Champion- Arnaud,
J. David-Ameline, and P. Moullier.
1998.
Factors influencing recombinant adeno-associated virus production.
Hum. Gene Ther.
9:695-706[Medline].
|
| 29.
|
Samulski, R. J.,
L. S. Chang, and T. Shenk.
1989.
Helper-free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression.
J. Virol.
63:3822-3828[Abstract/Free Full Text].
|
| 30.
|
Schimke, R. T.
1988.
Gene amplification in cultured cells.
J. Biol. Chem.
263:5989-5992[Free Full Text].
|
| 31.
|
Smith, R. H., and R. M. Kotin.
1998.
The Rep52 gene product of adeno-associated virus is a DNA helicase with 3'-to-5' polarity.
J. Virol.
72:4874-4881[Abstract/Free Full Text].
|
| 32.
|
Snyder, R. O.
1999.
Adeno-associated virus-mediated gene delivery.
J. Gene Med.
1:166-175[CrossRef][Medline].
|
| 33.
|
Wahl, G. M.
1989.
The importance of circular DNA in mammalian gene amplification.
Cancer Res.
49:1333-1340[Free Full Text].
|
| 34.
|
Walz, C.,
A. Deprez,
T. Dupressoir,
M. Dürst,
M. Rabreau, and J. R. Schlehofer.
1997.
Interaction of human papillomavirus type 16 and adeno-associated virus type 2 co-infecting human cervical epithelium.
J. Gen. Virol.
78:1441-1452[Abstract].
|
| 35.
|
Ward, P.,
F. B. Dean,
M. E. O'Donnell, and K. I. Berns.
1998.
Role of the adenovirus DNA-binding protein in in vitro adeno-associated virus DNA replication.
J. Virol.
72:420-427[Abstract/Free Full Text].
|
| 36.
|
Ward, P., and R. M. Linden.
2000.
A role for single-stranded templates in cell-free adeno-associated virus DNA replication.
J. Virol.
74:744-754[Abstract/Free Full Text].
|
| 37.
|
Ward, P.,
E. Urcelay,
R. Kotin,
B. Safer, and K. I. Berns.
1994.
Adeno-associated virus DNA replication in vitro: activation by a maltose binding protein/Rep 68 fusion protein.
J. Virol.
68:6029-6037[Abstract/Free Full Text].
|
| 38.
|
Weitzman, M. D.,
S. R. Kyostio,
R. M. Kotin, and R. A. Owens.
1994.
Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA.
Proc. Natl. Acad. Sci. USA
91:5808-5812[Abstract/Free Full Text].
|
| 39.
|
Wistuba, A.,
S. Weger,
A. Kern, and J. A. Kleinschmidt.
1995.
Intermediates of adeno-associated virus type 2 assembly: identification of soluble complexes containing Rep and Cap proteins.
J. Virol.
69:5311-5319[Abstract].
|
| 40.
|
Wonderling, R. S.,
S. R. Kyostio, and R. A. Owens.
1995.
A maltose-binding protein/adeno-associated virus Rep68 fusion protein has DNA-RNA helicase and ATPase activities.
J. Virol.
69:3542-3548[Abstract].
|
| 41.
|
Zhou, X.,
I. Zolotukhin,
D. S. Im, and N. Muzyczka.
1999.
Biochemical characterization of adeno-associated virus Rep68 DNA helicase and ATPase activities.
J. Virol.
73:1580-1590[Abstract/Free Full Text].
|
Journal of Virology, January 2001, p. 375-383, Vol. 75, No. 1
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.1.375-383.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Murphy, M., Gomos-Klein, J., Stankic, M., Falck-Pedersen, E.
(2007). Adeno-Associated Virus Type 2 p5 Promoter: a Rep-Regulated DNA Switch Element Functioning in Transcription, Replication, and Site-Specific Integration. J. Virol.
81: 3721-3730
[Abstract]
[Full Text]
-
Glauser, D. L., Saydam, O., Balsiger, N. A., Heid, I., Linden, R. M., Ackermann, M., Fraefel, C.
(2005). Four-Dimensional Visualization of the Simultaneous Activity of Alternative Adeno-Associated Virus Replication Origins. J. Virol.
79: 12218-12230
[Abstract]
[Full Text]
-
Musatov, S., Roberts, J., Pfaff, D., Kaplitt, M.
(2002). A cis-Acting Element That Directs Circular Adeno-Associated Virus Replication and Packaging. J. Virol.
76: 12792-12802
[Abstract]
[Full Text]
-
Qiao, C., Wang, B., Zhu, X., Li, J., Xiao, X.
(2002). A Novel Gene Expression Control System and Its Use in Stable, High-Titer 293 Cell-Based Adeno-Associated Virus Packaging Cell Lines. J. Virol.
76: 13015-13027
[Abstract]
[Full Text]
-
Nony, P., Tessier, J., Chadeuf, G., Ward, P., Giraud, A., Dugast, M., Linden, R. M., Moullier, P., Salvetti, A.
(2001). Novel cis-Acting Replication Element in the Adeno-Associated Virus Type 2 Genome Is Involved in Amplification of Integrated rep-cap Sequences. J. Virol.
75: 9991-9994
[Abstract]
[Full Text]